A UPLC–MS/MS method for quantification of 5α-androst-3β, 5, 6β-triol in human plasma: development, validation and its application in clinical pharmacokinetic study. (June 2017)

• Record Type: Journal Article
• Authors: Wang, Zhenlei; Wang, Huanhuan; Hu, Pei; Jiang, Ji; Zhao, Qian
• Is Part Of: Bioanalysis. Volume 9:Number 11(2017)
• Page Start: 873
• Page End: 885
• Publication Date: 2017-06
• Subjects: 5α-androst-3β, 5, 6β-triol -- human plasma -- ischemic stroke -- UPLC–MS/MS; Drugs -- Analysis -- Periodicals; 615.19005
• DOI: 10.4155/bio-2017-0035
• Languages: English
• ISSNs: 1757-6180

Abstract

Aim: 5α-androst-3β, 5, 6β-triol is a novel ischemic stroke drug under clinical development. The objective of this study was to develop and validate a simple ultraperformance liquid chromatography tandem mass spectrometry method for 5α-androst-3β, 5, 6β-triol in human plasma and its application in clinical pharmacokinetic study.Methodology & results: After being pretreated using an automatized solid-phase extraction procedure, plasma sample was separated on a Waters ® Acquity™ BEH C18 column (2.1 × 50 mm id, 1.7 mm) by an Acquity UPLC system and detected by an API 5500 triple quadrupole mass spectrometer, which was validated following international guidelines.Conclusion: A simple method was successfully validated over a concentration range of 2.00–500 ng/ml for 5α-androst-3β, 5, 6β-triol and applied to investigate its plasma pharmacokinetic profiles in healthy Chinese subjects.